Myriad Genetics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Myriad Genetics, Inc., (“Myriad" or the "Company") (NASDAQ:MYGN) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/myriad-genetics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Myriad’s stock price plummeted $3.00, or 41.3%, to close at $4.27 per share on May 7, 2025, thereby injuring investors. This massive valuation collapse followed the May 6, 2025, release of first quarter financial results, which revealed that total revenue of $196 million had declined by 3% year-over-year. Management specifically highlighted a 20% year-over-year drop in pharmacogenomics revenue, attributing the decline to UnitedHealthcare (UNH) “reducing coverage of GeneSight®.” Consequently, the Company lowered its financial guidance for the remainder of 2025 to reflect these disappointing quarterly results and a weakened “business outlook.” The market responded with extreme volatility to the combination of lost insurance coverage for a key product and the downward revision of future earnings expectations.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.